Newly Identified Molecular Subtypes Could Guide Treatment Decisions in Prostate Cancer

Excerpt:

“Researchers have identified 3 distinct molecular subtypes of primary prostate cancer that correlate with distant metastasis-free survival (DMFS) and response to radiation therapy.

“These subtypes, along with the standardization of genetic testing, will pave the way toward a more effective, personalized approach to prostate cancer treatment, said lead study author Daniel E. Spratt, MD, who presented the findings at the 2016 ASTRO Annual Meeting.

“Current methods of identifying a patient’s risk for recurrence are lacking, he explained.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


New Data Helps Doctors Zero in on Breast Cancer Risks, Treatments

“At Ricki Fairley’s annual check-up in 2012, doctors found a tiny lump. She was diagnosed with triple negative breast cancer, a less common and more aggressive form of the disease that has very few treatment options. Approximately 15 percent of all breast cancer cases are categorized as triple negative.

“Triple negative breast cancer can be effectively treated if the disease is caught early, and Fairley, now 58 years old, is living proof. She underwent a long course of aggressive chemotherapy and radiation and is now doing well.

“Triple negative is one of four subtypes of breast cancer, and a new report emphasizes how important it is for doctors to identify the risks and treatments for each. For example, triple negative cancers do not respond to certain hormonal therapies that can help other women.

“The nationwide data — published in the Journal of the National Cancer Institute and co-authored by the American Association of Central Cancer Registries, the American Cancer Society, the Centers for Disease Control and Prevention, and the National Cancer Institute at the National Institutes of Health — may help doctors identify which patients are at most risk for each type of breast cancer and which treatments may be most effective.”


Cancer Commons Publishes New Molecular Models of Lung Cancer and Melanoma

Cancer Commons aims to put the most up-to-date information about cancer treatment into the hands of patients. To keep this information current, Cancer Commons’ Chief Scientist Emma Shtivelman and collaborators periodically comb the scientific literature to compile and publish review papers that serve as “consensus models” of different cancer types and how they’re treated. Two new consensus models were recently published for lung cancer and melanoma in the scientific journal Oncotarget.

The new consensus models describe the molecular underpinnings of lung cancer and melanoma, and how different genetic mutations and other molecular-scale changes are used to develop different treatments. The models serve as the scientific foundation of the personalized, patient-friendly information Cancer Commons provides to lung cancer and melanoma patients, and they will be updated as new insights emerge.

Cancer Commons is also preparing a prostate cancer consensus model for publication. Consensus models for other cancer types may be published as we expand our services.

Both models are available free of charge on the Oncotarget website:

Lung Cancer

Melanoma